Senazodan

Senazodan (MCI 154) is a Ca²⁺ sensitiser, and also shows inhibition effect on PDE III^[1][2]. IC50 & Target: PDE III^[1] In Vitro: Senazodan seems to affect directly the actin-myosin crossbridge kinetics, and increase myosin ATPase activity^[1]. Senazodan produces a concentration-dependent increase in tension development. Senazodan enhances Ca²⁺ binding to myofilaments and to purified cardiac troponin C. Senazodan also enhances contractility in guinea-pig papillary muscles by inhibiting PDE III^[2]. Senazodan (0.1 nM~0.1 mM) shows that the contractile response of superior mesenteric arterie (SMA) to norepinephrine (NE) after hemorrhagic shock is significantly decreased as compared with the normal control group. Senazodan (0.01 mM) pretreatment prevents the effects of Ang II, and the concentration-response curve of Ca²⁺ is shifted to the right as compared with Ang II-alone group^[3]. In Vivo: Senazodan (0.1~2.0 mg/kg; left femoral vein catheterization infusion) decreases the pressor effect of norepinephrine (NE)^[3].
Senazodan (0.1 mg/kg; i.v.) makes LVSP, IP, MC, and Lo all increased significantly, while heart rate is not obviously changed and left ventricular end-diastolic pressure (LVEDP) is reduced remarkably^[4].